Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical …
MF Press, G Sauter, L Bernstein, IE Villalobos… - Clinical Cancer …, 2005 - AACR
Purpose: To critically assess the accuracy and reproducibility of human epidermal growth
factor receptor type 2 (HER-2) testing in outside/local community-based hospitals versus two …
factor receptor type 2 (HER-2) testing in outside/local community-based hospitals versus two …
[HTML][HTML] Alteration of topoisomerase II–alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy
…, R Guzman, A Santiago, IE Villalobos… - Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
Purpose Approximately 35% of HER2-amplified breast cancers have coamplification of the
topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of …
topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of …
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer
Purpose: Biomarkers from two randomized phase III trials were analyzed to optimize selection
of patients for lapatinib therapy. Experimental Design: In available breast cancer tissue …
of patients for lapatinib therapy. Experimental Design: In available breast cancer tissue …
[HTML][HTML] HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists guidelines with FISH …
…, JR Mackey, V Bee, Y Ma, I Villalobos… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose ASCO and the College of American Pathologists (ASCO-CAP) recently recommended
further changes to the evaluation of human epidermal growth factor receptor 2 gene (…
further changes to the evaluation of human epidermal growth factor receptor 2 gene (…
[HTML][HTML] Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831 …
…, RB Jenkins, C Kim, B Chen, I Villalobos… - Breast Cancer Research …, 2013 - Springer
A comprehensive, blinded, pathology evaluation of HER2 testing in HER2-positive/negative
breast cancers was performed among three central laboratories. Immunohistochemistry (IHC…
breast cancers was performed among three central laboratories. Immunohistochemistry (IHC…
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
…, MR Lackner, GA Pestano, A Santiago, I Villalobos… - Clinical Cancer …, 2015 - AACR
Purpose: To investigate the clinical relevance of PTEN in HER2-amplified and HER2-nonamplified
disease. Experimental Design: We assessed PTEN status in two large adjuvant …
disease. Experimental Design: We assessed PTEN status in two large adjuvant …
Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization …
MF Press, I Villalobos, A Santiago… - … of pathology & …, 2016 - meridian.allenpress.com
<sec id="st1"> <title>Context.— Evaluation of HER2 gene amplification by fluorescence in
situ hybridization (FISH) was changed by recent American Society of Clinical Oncology/…
situ hybridization (FISH) was changed by recent American Society of Clinical Oncology/…
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
…, RC Gagnon, TJ Grob, M Buyse, I Villalobos… - Molecular cancer …, 2017 - AACR
HER2/ERBB2 status is used to select patients for HER2-targeted therapy. HER2/ERBB2
amplification/overexpression of upper gastrointestinal (UGI) adenocarcinomas was determined …
amplification/overexpression of upper gastrointestinal (UGI) adenocarcinomas was determined …
Assessment of ERBB2/HER2 status in HER2-equivocal breast cancers by FISH and 2013/2014 ASCO-CAP guidelines
…, M Martin, V Valero, V Bee, Y Ma, I Villalobos… - JAMA …, 2019 - jamanetwork.com
Importance The 2013/2014 American Society of Clinical Oncology and College of American
Pathologists (ASCO-CAP) guidelines forHER2testing by fluorescence in situ hybridization (…
Pathologists (ASCO-CAP) guidelines forHER2testing by fluorescence in situ hybridization (…
HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
…, L Haeberle, A Gasparyan, IE Villalobos… - Breast cancer research …, 2014 - Springer
Gene amplification is an important factor for altered gene expression in breast cancers.
TOP2A-amplification often occurs concomitantly with HER2 amplification, and it has been …
TOP2A-amplification often occurs concomitantly with HER2 amplification, and it has been …